Streetbeat News

Price Targets

GHLD

JP Morgan analyst Richard Shane maintains an Underweight rating on Guild Holdings (NYSE:GHLD) but raises the price target from $15 to $16.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:21 pm

GPMT

Keefe, Bruyette & Woods analyst Jade Rahmani maintains an Underperform rating on Granite Point Mortgage (NYSE:GPMT) and lowers the price target from $3.25 to $2.75.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:20 pm

PCRX

RBC Capital has downgraded Pacira BioSciences (NASDAQ:PCRX) from Outperform to Sector Perform and lowered the price target from $37 to $14.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:19 pm

GSHD

JP Morgan analyst Pablo Singzon maintains a Neutral rating on Goosehead Insurance (NASDAQ:GSHD) but raises the price target from $65 to $77.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:19 pm

FTDR

JP Morgan analyst Cory Carpenter maintains an Overweight rating on Frontdoor (NASDAQ:FTDR) and raises the price target from $45 to $55.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:17 pm

CMTG

Keefe, Bruyette & Woods analyst Jade Rahmani maintains an Underperform rating on Claros Mortgage Trust (NYSE:CMTG) and lowers the price target from $8.5 to $8.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:17 pm

FMC

JP Morgan analyst Jeffrey Zekauskas maintains a Neutral rating on FMC (NYSE:FMC) and raises the price target from $50 to $59.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:15 pm

BLND

Keefe, Bruyette & Woods analyst Ryan Tomasello maintains a Market Perform rating on Blend Labs (NYSE:BLND) and raises the price target from $3 to $3.25.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:14 pm

ETR

JP Morgan analyst Jeremy Tonet maintains an Overweight rating on Entergy (NYSE:ETR) and raises the price target from $131 to $141.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:13 pm

EWTX

JP Morgan analyst Tessa Romero maintains an Overweight rating on Edgewise Therapeutics (NASDAQ:EWTX) and raises the price target from $30 to $31.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:12 pm